Search Results 1191-1200 of 16245 for monoclonal antibody

1. A Study of the Safety and Effectiveness of QPI-1002 for the Prevention of Delayed Graft Function in Transplant Recipients from Older Kidney Donors who have Died - Mayo Clinic

   ... monoclonal antibodies per center standard of care. Must be up-to-date on ... Has a positive T- or B-cell flow cross-match AND donor specific anti-HLA antibody ...

2. A Study to Investigate Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache - Mayo Clinic

   Has previously received any CGRP ligand or receptor targeted monoclonal antibody. Eligibility last updated 1/19/22. Questions regarding updates should be ...

3. Cough - Mayo Clinic

   Monoclonal antibody drugs · Mort Crim and Cancer · Mouth sores caused by cancer treatment: How to cope · Nasal Cleaning · Neti pot: Can it clear my nose? No ...

4. Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST - Mayo Clinic

   For prior biological therapies (e.g., monoclonal antibodies with a half-life longer than 3 days), the interval must be at least 28 days prior to the first dose ...

5. Aficamten in a Pediatric Population with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Mayo Clinic

   Current or previous use of drugs known to cause cardiomyopathy (eg, anthracyclines, monoclonal antibodies [trastuzumab], alkylating agents [cyclophosphamide] ...

6. Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma - Mayo Clinic

   ... antibody. Patients must be at least 90 days since an autologous stem cell transplant, if performed. 3.1.5 Patients must have measurable disease per IMWG ...

7. A Study to Evaluate Induction Chemotherapy with ABVD Followed by Brentuximab Vedotin Consolidation in Previously-untreated, Non-bulky Stage I or II Hodgkin Lymphoma - Mayo Clinic

   For this research study, the use of brentuximab vedotin in newly diagnosed Hodgkin lymphoma is considered investigational. Brentuximab vedotin is an antibody ...

8. Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant - Mayo Clinic

   ... antibody specific for their deceased donor. It is our hypothesis that blockade of terminal complement activation with eculizumab at the time of transplant ...

9. Autoimmune Hemolytic Anemias Clinical Trials - Mayo Clinic Research

   The purpose of this study is to assess antibody activity IN vitro in cold agglutinin disease (CAD) patients. Safety, Tolerability, Pharmacokinetics and ...

10. Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis - Mayo Clinic

    Secondary or familial amyloidosis; · Life expectancy of < 3 months; · Symptomatic multiple myeloma; · Hypersensitivities to other monoclonal antibodies; · Known HIV ...